Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

A new head-to-head study reveals tirzepatide achieves 47% more weight loss than semaglutide in people with obesity but without diabetes, highlighting its superior effectiveness and cardiometabolic ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Global Sustainable Aviation Fuel (SAF) Production Capacity Outlook to 2030 (2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

SAF Holland reported a revenue decline of 11% year-over-year for Q1 2025, reaching €449.2 million. Despite the revenue drop, the company maintained a robust adjusted EBIT margin of 9.5%.

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "United States Biodiesel Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com ...

A majority of pet owners would prefer to spend time with their fluffy friends when they are stressed rather than with their partners, according to new research. A global survey of 30,000 pet ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...